Amendments to the Specification:

Please amend the paragraph on page 7, line 42 to page 8, line 5 as follows:

Figure 4B depicts the effect of various concentrations of 21x on reporter expression in *E. coli* strains that carry *rrnB* P1 promoter constructs (the sequences for which are presented in Fig. ~~9A~~ 4A), fused to a *lacZ* reporter on the chromosome as a phage mono-lysogen, as indicated in the figure. Cells were incubated with or without 21x for 24 hrs and promoter activities assayed following treatment. Promoter activities are expressed as a percentage of basal promoter activity. All samples were in triplicate, the error bars represent standard errors of the mean (SEM) for three separate experiments.

Please amend the paragraph on page 8, lines 11-15 as follows:

Figure 6 depicts the results of DNA binding studies with the modified UL9 DNA response sequences presented in Fig. ~~9A~~ 5 and ^{32}P labeled oligos, incubated with various concentrations of 21x. The modified sequences include "YK 202LX" (shown as diamonds, SEQ ID NO:18), "YK 202RX-A" (shown as squares, SEQ ID NO:19), and "YK 202RX" (shown as triangles, SEQ ID NO:21)

Please amend the paragraph on page 58, lines 5-14 as follows:

Expression of the firefly reporter using various engineered minimal CMV promoter constructs was analyzed in the presence or absence of various amount of exogenous NF-κB plasmid (pS50 and pS65 for the p50 and p65 NF-κB subunit, respectively). As shown in Table 6, the presence of NF-κB response elements in p2MC, p4MC, pBK2MC augmented the activity of the promoters approximately 4 to 17 fold relative to the activity of promoters lacking the NF-κB response element (pMC and pBKMC). This effect was incrementally increased based on the number of NF-κB response elements. These results suggest that NF-κB acted as the major activator for the promoters with NF-κB response element. Results are reported as normalized firefly luciferase activity relative to Renilla luciferase activity and as absolute firefly luciferase

activity ~~(-)~~.

Please amend the paragraph on page 59, lines 19-23 as follows:

In Figure 9, ~~the transcriptional regulatory protein-DNA response site is indicated as bolded and uppercase, introduced drug binding sites are indicated in lowercase and potential drug binding sites are indicated as ( ) or [ ]. Both~~ both of oligonucleotides tested, SEQ ID NO:34 and SEQ ID NO:35, have introduced drug binding sites which overlap the lacR binding site on both sides of the lacO sequence.

Please amend the paragraph on page 59, lines 24-25 as follows:

A gel mobility shift assay was carried out as described above for UL9, and the results are presented in ~~Figs. 10A and B~~ Fig. 10.